Functional Outcome of Platelet-Rich Plasma vs Recombinant Platelet-Derived Growth Factor in the Management of Diabetic Foot Ulcers
Main Article Content
Abstract
Background: Diabetic foot ulcers (DFUs) are a severe complication of diabetes mellitus, frequently resulting in lower limb amputations. Platelet-rich plasma (PRP) and recombinant platelet-derived growth factor (rPDGF) have been explored as therapeutic options to enhance wound healing. This study aims to compare the effectiveness of PRP versus rPDGF in managing DFUs.
Methods: This cross-sectional study was conducted at the Surgery Outpatient Department of Sree Balaji Medical College & Hospital from January to December 2023. A total of 52 diabetic patients with Wagner’s Grade 1- or 2-foot ulcers were randomly assigned to receive either PRP therapy or rPDGF treatment, with follow-up visits every four weeks over 12 weeks. Baseline characteristics, healing outcomes, and patient satisfaction were analyzed using descriptive statistics and the Chi-square test, with significance set at p < 0.05.
Results: Both groups showed comparable baseline characteristics, including age (p = 0.619), gender distribution (p = 0.780), and ulcer size (p = 0.961). There were no significant differences in healing time (p = 0.544), pain reduction (p = 0.388), or complication rates (p = 0.492). However, patient satisfaction was significantly higher in the PRP group (p < 0.001). A trend towards a higher infection rate was observed in the rPDGF group (p = 0.771).
Conclusion: PRP and rPDGF are both effective in promoting wound healing in DFUs, with PRP offering higher patient satisfaction and a lower trend in infection rates. Larger randomized trials are needed to confirm these findings and explore long-term outcomes. Integrating therapies like PRP into standard wound care protocols could significantly improve the quality of life for diabetic patients and reduce the risk of amputations.